NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Senti, in the Car-t trial you are analyzing, when they say “all” tumors regressed (starting day 133), they were not talking about tumors 1, 2 or 3, I think. They believe those sites remained stable after 100% resection.

They are counting tumor stabilization to extend their 7.5 month “dramatic” response claim.

That makes this paragraph by them a bit disingenuous, because it lumps in stabilization with tumor response.

This dramatic clinical response was sustained for 7.5 months after the initiation of CAR T-cell therapy, and none of these initial tumors (tumors 1 through 7 and spinal tumors) recurred.

They are actually strictly talking about 4, 5, 6, 7 in addition to spinal tumor 8. They refer to “table S3”, and upon reviewing, only “tumors” 4, 5, 6, and 8 are discussed there.

I will bring up a peculiar anomaly. The mri and pet scan scheduled for day 156 (an important time) was cancelled due to lack of product?

The backdrop of this case report is that no other GBM patients that were in the 65 patient trial had a response.

I think your best argument is that the authors clearly overstated the length of response.